Overlays and hsbs start looking

Quote












anonymous said:
Former DM that recently left here. There is no way they can touch overlays without including embedded positions. Everyone was hired with the same qualifications and standards. Legally they will have to put you all in a pool and have a fair way of reorganizing. Expect to interview for the new territory wherever you are, in either role. I don't have inside information beyond this. If you aren't locked in, start looking. If you are, best of luck. Work on your interview skills and engage your network.
Click to expand...
 








anonymous said:
Exactly! When companies reorganize at the top, the sales force follows. There are big changes coming so get prepared.
Click to expand...
Accounts were communicated this week. Most KAMSs and HSBS know if they will keep their jobs. HSBM still in limbo until regions are aligned. HSBS without a KAM account also still in limbo. TBS will be last to know for new structure.
 












The profits from Jardiance are being split with Lilly so BI’s profit margin is not as high with it. Don’t forget - there are a hell of a lot of Lilly reps selling it and they have better access with diabetes products because they sell the injectables as well. The BI diabetes reps are not as valuable as you think. Lol
 




















Regional alignments by therapeutic area, health system and CBDs will be announced by end of August. Effective October 1st. This is why PC ends in September. Your territory will look different in Q4.
 








anonymous said:
We are becoming a specialty company. Primary care sales will get smaller and smaller until end of drug lifespan. No primary care drugs in pipeline.
Click to expand...

This seems highly likely. Or at least somewhat close to the truth. We have nothing at all in the pipeline before 3-4 years out, outside of line extensions and expanded indications. Respiratory is gone somewhat soon. Ofev is doing well. We can’t all be selling jardiance. Nothing left til like 2025.
 




anonymous said:
This seems highly likely. Or at least somewhat close to the truth. We have nothing at all in the pipeline before 3-4 years out, outside of line extensions and expanded indications. Respiratory is gone somewhat soon. Ofev is doing well. We can’t all be selling jardiance. Nothing left til like 2025.
Click to expand...
Wrong, Humaria biosimiliar has official 2022 launch date, 6 BILLION dollar drug.
 








It’s 2019. Primary care med sales exists at the payer level. If you’re selling pcp drugs you’re riding a dinosaur to the finish line.l
 
Last edited by a moderator:




anonymous said:
Wrong, Humaria biosimiliar has official 2022 launch date, 6 BILLION dollar drug.
Click to expand...

The current thought is that this wouldn't even have a sales force. 0 reps. Even if it did, there are many reasons this wouldn't come even close to the 6 billion dollars that Humira has done. If THAT was what you are waiting for, you're going to be severely disappointed to see the outcome.

Go look at our pipeline, a simple google search will produce the results. It's also the same one on town hall replays. https://www.boehringer-ingelheim.co...t/pipeline/research-and-development-pipeline?

NO new drugs beyond phase 2. A large % of drugs fail in phase 2. All line extensions and expanded indications. Face reality folks. Nothing in the pipeline. We are going to have to get much smaller and hope that some of those phase 2 drugs become reality in about 5 years time.
 




Top Bottom
Back
Quote